Hye-Lim Jang

Impact of <i>KRAS</i> Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Seung Tae Kim, Do Hyoung Lim, Kee‐Taek Jang et al. · Molecular Cancer Therapeutics · 2011 · 145 citations

Medicine, Oncology, Pathology +15

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification

Seung Tae Kim, Hye-Lim Jang, Su Jin Lee et al. · Molecular Cancer Therapeutics · 2014 · 37 citations

Medicine, Oncology, Pharmacology +17

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

Seung Tae Kim, Kee‐Taek Jang, Su Jin Lee et al. · BMC Cancer · 2015 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Seung Tae Kim, Kee‐Taek Jang, Heung-Moon Jang et al. · Translational Oncology · 2015 · 21 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer

Seung Tae Kim, Hye-Lim Jang, Jeeyun Lee et al. · Translational Oncology · 2015 · 10 citations · Full text

Medicine, Molecular Medicine, Oncology +16